麻省理工学院和哈佛研究人员创建了强化的CAR-NK细胞,抵制免疫排斥,推动“现成”癌症治疗。 MIT and Harvard researchers created enhanced CAR-NK cells that resist immune rejection, advancing "off-the-shelf" cancer therapies.

麻省理工学院和哈佛医学院研究人员的一项新研究已经开发出一种单步遗传工程方法,用于加强CAR-NK细胞,以便进行癌症治疗。 A new study by MIT and Harvard Medical School researchers has developed a one-step genetic engineering method to enhance CAR-NK cells for cancer treatment. 通过修改捐赠细胞来减少HLA1级蛋白质,并增加能增强致癌能力的基因,这些细胞避免免疫排斥并存活更长的时间。 By modifying donor cells to reduce HLA class 1 proteins and adding genes that boost cancer-killing ability, the cells evade immune rejection and survive longer. 在人性化的老鼠模型中,所设计的细胞有效地针对癌症,而没有受到宿主免疫系统的攻击。 In humanized mouse models, the engineered cells effectively targeted cancer without being attacked by the host immune system. 这一进展使“现成”的CAR-NK疗法更接近于现实,有可能使癌症患者得到更快、更容易获得的治疗。 The advance brings “off-the-shelf” CAR-NK therapies closer to reality, potentially enabling faster, more accessible treatments for cancer patients. 研究结果发表在《自然通信》中。 The findings were published in Nature Communications.